Keio University · Faculty of Medicine / Graduate School of Medicine

Research keywordshepatocellular carcinoma・lenvatinib・transarterial chemoembolization・atezolizumab plus bevacizumab・decompensated cirrhosis・liver transplantation・gut-liver axis・primary biliary cholangitis

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Advantage of Scheduled Upfront Lenvatinib Administration Followed by Transarterial Chemoembolization Therapy Over Lenvatinib Monotherapy in Patients With Unresectable Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Cohort Study.2026
• 「飲」「食」と消化器疾患の新知見 肥満進展におけるCCR9-CCL25を介した小腸-内臓脂肪連関の検討2025 · 日本消化器病学会雑誌
• Trends and Barriers in Liver Transplantation for Patients With Decompensated Cirrhosis: A 15-Year Single-Center Cohort at a Japanese Center2025 · Transplantation Proceedings 57
• Continuation of atezolizumab plus bevacizumab beyond initial progressive disease: clinical benefits in patients with unresectable hepatocellular carcinoma – a multicenter cohort study2025 · Frontiers in Immunology 16

• 原発性硬化性胆管炎のAhRを介した病態解明およびAhR ligandによる新規治療開発2025 · -
• ”腸-肝臓-脳相関”で構成される自律神経回路による大腸癌の新規病態解明と治療開発2022
• "腸-肝臓-脳相関"で構成される自律神経回路による大腸癌の新規病態解明と治療開発2022 · -
• インジゴ化合物による新規原発性硬化性胆管炎治療法の開発2020 · -

• Official profile